Citius Oncology (NASDAQ:CTOR) Releases Earnings Results, Hits Expectations

Citius Oncology (NASDAQ:CTOR) released its quarterly earnings data on Friday. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06), FiscalAI reports. The firm had revenue of $3.94 million during the quarter, compared to analysts’ expectations of $4.37 million.

Citius Oncology Stock Up 3.4%

Shares of NASDAQ:CTOR opened at $1.22 on Friday. The company has a quick ratio of 0.11, a current ratio of 0.56 and a debt-to-equity ratio of 0.08. Citius Oncology has a 52-week low of $0.55 and a 52-week high of $6.19. The stock’s fifty day simple moving average is $1.12 and its 200-day simple moving average is $1.50. The company has a market capitalization of $107.70 million, a P/E ratio of -3.59 and a beta of 3.09.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Citius Oncology has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after purchasing an additional 8,411 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Citius Oncology during the third quarter valued at approximately $36,000. Geode Capital Management LLC boosted its position in Citius Oncology by 179.0% during the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after acquiring an additional 36,758 shares during the last quarter. Jane Street Group LLC purchased a new stake in Citius Oncology in the 2nd quarter worth approximately $465,000. Finally, Armistice Capital LLC acquired a new position in Citius Oncology in the 3rd quarter valued at $15,582,000. 70.52% of the stock is currently owned by hedge funds and other institutional investors.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.